Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences

Published Oct 11 2021 at 11:13 AM GMT
  • Tampa, Fla.-based Pacira BioSciences Inc said Monday it is acquiring Flexion Therapeutics Inc.
  • , based in Burlington, Mass., for $8 a share in cash, plus a non-tradeable contingent value right (CVR) worth up to $8.50 a share in cash, in a deal aimed at expanding its position in non-opioid pain management.
  • The CVR is payable based on the company meeting certain sales and regulatory milestones.
  • Flexion's lead product, ZILRETTA(R) (triamcinolone acetonide extended-release injectable suspension) is the first and only FDA-approved treatment for osteoarthritis knee pain using extended-release microsphere technology, the companies said in a joint statement.
  • It also offering non-opioid treatments for musculoskeletal conditions, including postsurgical pain and low back pain.



  • Published Oct 11, 2021 11:13 AM GMT